Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
The therapeutic efficacies of the newer beta-lactam antibiotics piperacillin, azlocillin and aztreonam were compared with the efficacies of ticarcillin and tobramycin in a guinea pig model of experimental Pseudomonas aeruginosa pneumonia. For animals challenged with 2 X 10(8) CFU, tobramycin treatment resulted in survival rates and intrapulmonary killing of pseudomonads which were significantly greater than those found with any of the beta-lactam agents. There were no significant differences noted among the individual beta-lactam agents. When animals were challenged with 200-fold-fewer organisms (10(6) CFU), there was no significant difference between the efficacy of tobramycin and those of the various beta-lactams. These data suggest that tobramycin is particularly valuable in treating more severe P. aeruginosa pneumonia, whereas a number of different beta-lactam agents are of equivalent value in less severe lung infections.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001390:Azlocillin; D001398:Aztreonam; D006168:Guinea Pigs; D010406:Penicillins / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D013982:Ticarcillin / Q000627:therapeutic use; D014031:Tobramycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D010406:Penicillins; D013982:Ticarcillin; D001398:Aztreonam; D001390:Azlocillin; D014031:Tobramycin; D010878:Piperacillin